Performance of the HAS-BLED high bleeding-risk category, compared to ATRIA and HEMORR2HAGES in patients with atrial fibrillation: a systematic review and meta-analysis

Journal of Interventional Cardiac Electrophysiology

Volumn 40, Issue 3, 2014, Pages 277-284

  Caldeira, Daniel ^a,b,c   Costa, João ^a,b   Fernandes, Ricardo M ^a,b   Pinto, Fausto J ^b   Ferreira, Joaquim J ^a,b  

^a INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^b UNIVERSITY OF LISBON   (Portugal)

^c HOSPITAL GARCIA DE ORTA   (Portugal)

Author keywords

Bleeding; Clinical prediction rule; HAS BLED; Hemorrhage; Score system

Indexed keywords

ATRIAL FIBRILLATION; CEREBRAL HEMORRHAGE; COMPARATIVE STUDY; COMPLICATION; DECISION SUPPORT SYSTEM; HEMORRHAGE; HUMAN; META ANALYSIS; PROCEDURES; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY;

ATRIAL FIBRILLATION; CEREBRAL HEMORRHAGE; DECISION SUPPORT TECHNIQUES; HEMORRHAGE; HUMANS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY;

EID: 84930001046     PISSN: 1383875X     EISSN: 15728595     Source Type: Journal    
DOI: 10.1007/s10840-014-9930-y     Document Type: Review

References (28)

1. Lip, G. Y., Andreotti, F., Fauchier, L., Huber, K., Hylek, E., Knight, E., et al. (2011). Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis. Europace, 13, 723–746.
2. Camm, A. J., Kirchhof, P., Lip, G. Y., Schotten, U., Savelieva, I., Ernst, S., et al. (2010). Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace, 12(10), 1360–1420.
3. Camm, A. J., Lip, G. Y., De Caterina, R., Savelieva, I., Atar, D., & Hohnloser, S. H. (2012). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation—developed with the special contribution of the European Heart Rhythm Association. Europace, 14, 1385–1413.
4. Hart, R. G., Benavente, O., McBride, R., & Pearce, L. A. (1999). Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Annals of Internal Medicine, 131, 492–501.
5. Miller, C. S., Grandi, S. M., Shimony, A., Filion, K. B., & Eisenberg, M. J. (2012). Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. The American Journal of Cardiology, 10, 453–460.
6. Andersen, L. V., Vestergaard, P., Deichgraeber, P., Lindholt, J. S., Mortensen, L. S., & Frost, L. (2008). Warfarin for the prevention of systemic embolism in patients with non-valvular atrial fibrillation: a meta-analysis. Heart, 94, 1607–1613.
7. Agarwal, S., Hachamovitch, R., & Menon, V. (2012). Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation: a meta-analysis. Archives of Internal Medicine, 172, 623–631.
8. Pisters, R., Lane, D. A., Nieuwlaat, R., de Vos, C. B., Crijns, H. J., & Lip, G. Y. (2010). A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest, 138, 1093–1100.
9. Gage, B. F., Yan, Y., Milligan, P. E., Waterman, A. D., Culverhouse, R., & Rich, M. W. (2006). Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). American Heart Journal, 151, 713–719.
10. Fang, M., Go, A., Chang, Y., Borowsky, L. H., Pmernacki, N. K., Udaltsova, N., et al. (2010). Abstract 16443: Development of a new risk stratification scheme to predict warfarin-associated hemorrhage: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. Circulation, 122, A16443.
11. Moons, K. G., Royston, P., Vergouwe, Y., Grobbee, D. E., & Altman, D. G. (2009). Prognosis and prognostic research: what, why, and how? BMJ, 338, b375.
12. Hemingway, H., Croft, P., Perel, P., Hayden, J. A., Abrams, K., Timmis, A., et al. (2013). Prognosis research strategy (PROGRESS) 1: a framework for researching clinical outcomes. BMJ, 346, e5595.
13. Whiting, P., Rutjes, A. W., Reitsma, J. B., Bossuyt, P. M., & Kleijnen, J. (2003). The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Medical Research Methodology, 3, 25.
14. Glas, A. S., Lijmer, J. G., Prins, M. H., Bonsel, G. J., & Bossuyt, P. M. (2003). The diagnostic odds ratio: a single indicator of test performance. Journal of Clinical Epidemiology, 56, 1129–1135.
15. Oosterhuis, W. P., Niessen, R. W., & Bossuyt, P. M. (2000). The science of systematic reviewing studies of diagnostic tests. Clinical Chemistry and Laboratory Medicine, 38, 577–588.
16. Higgins, J. P., & Thompson, S. G. (2002). Quantifying heterogeneity in a meta-analysis. Statistics in Medicine, 21, 1539–1558.
17. Olesen, J. B., Lip, G. Y., Hansen, P. R., Lindhardsen, J., Ahlehoff, O., Andersson, C., et al. (2011). Bleeding risk in ‘real world’ patients with atrial fibrillation: comparison of two established bleeding prediction schemes in a nationwide cohort. Journal of Thrombosis and Haemostasis, 9, 1460–1467.
18. Friberg, L., Rosenqvist, M., & Lip, G. Y. (2012). Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. European Heart Journal, 33, 1500–1510.
19. Apostolakis, S., Lane, D. A., Guo, Y., Buller, H., & Lip, G. Y. (2012). Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with atrial fibrillation) study. Journal of the American College of Cardiology, 60, 861–867.
20. Apostolakis, S., Lane, D. A., Guo, Y., Buller, H., & Lip, G. Y. (2013). Performance of the HEMORR2HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in nonwarfarin anticoagulated atrial fibrillation patients. Journal of the American College of Cardiology, 61, 386–387.
21. Roldán, V., Marín, F., Fernández, H., Manzano-Fernandez, S., Gallego, P., Valdés, M., et al. (2013). Predictive value of the HAS-BLED and ATRIA bleeding scores for the risk of serious bleeding in a "real-world" population with atrial fibrillation receiving anticoagulant therapy. Chest, 143, 179–184.
22. Seet, R. C., Rabinstein, A. A., Christianson, T. J., Petty, G. W., & Brown, R. D., Jr. (2013). Bleeding complications associated with warfarin treatment in ischemic stroke patients with atrial fibrillation: a population-based cohort study. Journal of Stroke and Cerebrovascular Diseases, 22, 561–569.
23. Schulman, S., Kearon, C., & Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. (2005). Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. Journal of Thrombosis and Haemostasis, 3, 692–694.
24. Hamon, M., Filippi-Codaccioni, E., Riddell, J. W., & Lepage, O. (2007). Prognostic impact of major bleeding in patients with acute coronary syndromes. A systematic review and meta-analysis. EuroIntervention, 3, 400–408.
25. Ruiz-Nodar, J. M., Marín, F., Roldán, V., Valencia, J., Manzano-Fernández, S., Caballero, L., et al. (2012). Should we recommend oral anticoagulation therapy in patients with atrial fibrillation undergoing coronary artery stenting with a high HAS-BLED bleeding risk score? Circulation. Cardiovascular Interventions, 5, 459–466.
26. Lip, G. Y., Banerjee, A., Lagrenade, I., Lane, D. A., Taillandier, S., & Fauchier, L. (2012). Assessing the risk of bleeding in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation project. Circulation. Arrhythmia and Electrophysiology, 5, 941–948.
27. Smith, J. G., Wieloch, M., Koul, S., Braun, O. Ö., Lumsden, J., Rydell, E., et al. (2012). Triple antithrombotic therapy following an acute coronary syndrome: prevalence, outcomes and prognostic utility of the HAS-BLED score. EuroIntervention, 8, 672–678.
28. Omran, H., Bauersachs, R., Rübenacker, S., Goss, F., & Hammerstingl, C. (2012). The HAS-BLED score predicts bleedings during bridging of chronic oral anticoagulation. Results from the national multicentre BNK Online bRiDging REgistRy (BORDER). Thrombosis & Haemostasis, 108, 65–73.